Upcoming Biotech Catalysts
Public preview of selected small-cap biotech catalyst timing.
| Company | Ticker | Catalyst | Timing | Asset | Confidence |
|---|---|---|---|---|---|
| BioVie Inc | BIVI | Clinical Trial Completion | 2026-08 | NE3107 | Low |
| Cel-Sci Corp | CVM | Clinical Trial Completion | 2026-08 | Hypothermia | Low |
| Ensysce Biosciences Inc | ENSC | Clinical Trial Completion | 2026-08 | PF614 capsule | Low |
| IGC Pharma Inc | IGC | Clinical Trial Completion | 2026-08 | IGC-AD1-Active | Low |
| Mustang Bio Inc | MBIO | Clinical Trial Completion | 2026-08-06 | cyclophosphamide | Low |
| CervoMed Inc | CRVO | Clinical Trial Completion | 2026-09 | Neflamapimod | Low |
| Boundless Bio Inc | BOLD | Clinical Trial Completion | 2026-09-30 | BBI-355 | Low |
| Cocrystal Pharma Inc | COCP | Clinical Trial Completion | 2026-10-01 | CDI-988 | Low |
| CDT Equity Inc | CDT | Clinical Trial Completion | 2026-10-20 | Litifilimab | Low |
| Atossa Therapeutics Inc | ATOS | Clinical Trial Completion | 2026-11 | (Z)-endoxifen | Low |
| Kiora Pharmaceuticals Inc | KPRX | Clinical Trial Completion | 2026-11 | KIO-104 | Low |
| MetaVia Inc | MTVA | Clinical Trial Completion | 2026-11-09 | DA-1726 | Low |
| Skye Bioscience Inc | SKYE | Clinical Trial Completion | 2026-11-20 | Nimacimab injection | Low |
| Alzamend Neuro Inc | ALZN | Clinical Trial Completion | 2026-12 | AL001 | Low |
| BioCardia Inc | BCDA | Clinical Trial Completion | 2026-12 | CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs) | Low |
| Gossamer Bio Inc | GOSS | Clinical Trial Completion | 2026-12 | Seralutinib | Low |
| Traws Pharma Inc | TRAW | Clinical Trial Completion | 2026-12 | TRX-100 | Low |
| Serina Therapeutics Inc | SER | Clinical Trial Completion | 2026-12-08 | mRNA-1645-eODGT8 | Low |
| 60 Degrees Pharmaceuticals Inc | SXTP | Clinical Trial Completion | 2026-12-08 | mRNA-1645-eODGT8 | Low |
| Psyence Biomedical Ltd | PBM | Clinical Trial Completion | 2026-12-30 | Psilocybin therapy | Low |
| Actuate Therapeutics Inc | ACTU | Clinical Trial Completion | 2026-12-31 | FOLFIRNINOX | Low |
| Actinium Pharmaceuticals Inc | ATNM | Clinical Trial Completion | 2026-12-31 | Actinium Ac 225 DOTATATE RYZ101 | Low |
| 60 Degrees Pharmaceuticals Inc | SXTP | Clinical Trial Completion | 2026-12-31 | Whole-Body Electrical Muscle Stimulation (WB-EMS) Training | Low |
| CalciMedica Inc | CALC | Clinical Trial Completion | 2027-01 | CM4620 | Low |
| IN8bio Inc | INAB | Clinical Trial Completion | 2027-01 | EAGD T-cell infusion (Phase I) | Low |
| Intensity Therapeutics Inc | INTS | Clinical Trial Completion | 2027-01 | Pirtobrutinib | Low |
| Azitra Inc | AZTR | Clinical Trial Completion | 2027-01-15 | ATR04-484 | Low |
| Apollomics Inc | APLM | Clinical Trial Completion | 2027-01-31 | APL-101 | Low |
| Creative Medical Technology Holdings Inc | CELZ | Clinical Trial Completion | 2027-01-31 | CELZ-201 Administration | Low |
| Grace Therapeutics Inc | GRCE | Clinical Trial Completion | 2027-02 | DISC-3405 | Low |
| Rein Therapeutics Inc | RNTX | Clinical Trial Completion | 2027-02 | DISC-3405 | Low |
| Xilio Therapeutics Inc | XLO | Clinical Trial Completion | 2027-02 | XTX301 | Low |
| Lantern Pharma Inc | LTRN | Clinical Trial Completion | 2027-02-01 | STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle. | Low |
| Astria Therapeutics | ATXS | Clinical Trial Completion | 2027-03 | Navenibart | Low |
| Marker Therapeutics Inc | MRKR | Clinical Trial Completion | 2027-03 | capsinoid supplementation | Low |
| Taysha Gene Therapies | TSHA | Clinical Trial Completion | 2027-03-12 | TSHA-101 | Low |
| Marker Therapeutics Inc | MRKR | Clinical Trial Completion | 2027-03-31 | ELEVIDYS | Low |
| 60 Degrees Pharmaceuticals Inc | SXTP | Clinical Trial Completion | 2027-04-01 | NPX372 | Low |
| Bolt Biotherapeutics Inc | BOLT | Clinical Trial Completion | 2027-05 | BDC-4182 | Low |
| Telomir Pharmaceuticals Inc | TELO | Clinical Trial Completion | 2027-05 | Zn-Telomir | Low |
| Cns Pharmaceuticals Inc | CNSP | Clinical Trial Completion | 2027-06 | Xevinapant | Low |
| Rein Therapeutics Inc | RNTX | Clinical Trial Completion | 2027-06 | Selinexor 60 mg | Low |
| Sensei Biotherapeutics Inc | SNSE | Clinical Trial Completion | 2027-06 | SNS-101 (anti-VISTA) | Low |
| Tempest Therapeutics Inc | TPST | Clinical Trial Completion | 2027-07 | Pentosan Polysulfate Sodium twice weekly | Low |
| Acurx Pharmaceuticals Inc | ACXP | Presentation | October 2025 | n/a | Low |
| Acurx Pharmaceuticals Inc | ACXP | Data Readout | Timing not specified | n/a | Low |
| Adial Pharmaceuticals Inc | ADIL | Corporate Update | Timing not specified | n/a | Low |
| Alzamend Neuro Inc | ALZN | Topline Data | March 2026 | n/a | Low |
| Artelo Biosciences Inc | ARTL | Data Readout | Timing not specified | n/a | Low |
| Aspire Biopharma Holdings Inc | ASBP | Corporate Update | July 2025 | n/a | Low |
| Atossa Therapeutics Inc | ATOS | Data Readout | Timing not specified | n/a | Low |
| Atossa Therapeutics Inc | ATOS | Corporate Update | Timing not specified | n/a | Low |
| Atara Biotherapeutics Inc | ATRA | FDA Meeting | January 2025 | n/a | Low |
| BioCardia Inc | BCDA | Corporate Update | Q4 2026 | n/a | Low |
| BioRestorative Therapies Inc | BRTX | Data Readout | Timing not specified | n/a | Low |
| Cellectar Biosciences Inc | CLRB | Corporate Update | Timing not specified | n/a | Low |
| Cellectar Biosciences Inc | CLRB | Data Readout | Timing not specified | n/a | Low |
| Cellectar Biosciences Inc | CLRB | Presentation | Timing not specified | n/a | Low |
| Curis Inc | CRIS | Corporate Update | Timing not specified | n/a | Low |
| Curis Inc | CRIS | Corporate Update | October 2015 | CA-170 | Low |
| Cadrenal Therapeutics Inc | CVKD | Corporate Update | December 2025 | n/a | Low |
| Cadrenal Therapeutics Inc | CVKD | FDA Meeting | Timing not specified | CAD-1005 | Low |
| Dare Bioscience Inc | DARE | Corporate Update | Timing not specified | n/a | Low |
| Dare Bioscience Inc | DARE | Corporate Update | Q2 2026 | n/a | Low |
| Dare Bioscience Inc | DARE | Interim Data | July 2025 | n/a | Low |
| Dare Bioscience Inc | DARE | IND Filing | July 2025 | n/a | Low |
Subscribe for full catalyst scoring.
Public tables hide binary risk, upside relevance, dilution risk, and internal analyst notes.
Get the free weekly watchlist